We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.
MAPK/ERK pathway
From Proteopedia
(Difference between revisions)
| Line 43: | Line 43: | ||
One effect of MAPK activation is to alter the translation of mRNA to proteins. | One effect of MAPK activation is to alter the translation of mRNA to proteins. | ||
====MAPK phosphorylates the 40S [[ribosomal protein S6 kinase]] (RSK). RSK phosphorylates [[ribosomal protein S6]].==== | ====MAPK phosphorylates the 40S [[ribosomal protein S6 kinase]] (RSK). RSK phosphorylates [[ribosomal protein S6]].==== | ||
| + | |||
| + | ====MAPK can phosphorylate [[C-myc]]==== | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 14:08, 17 February 2022
| |||||||||||
References
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089
